



NEWER ANTIMICROBIAL AGENTS: A SYSTEMATIC REVIEW

Mudasir Maqbool¹ and Geer Mohamed Ishaq^{1*}

¹Department of Pharmaceutical Sciences, University of Kashmir, Hazratbal Srinagar-190006, Jammu and Kashmir, India

*Corresponding Author Email: ishaggeer@gmail.com

ABSTRACT

Antibiotics are one of the most commonly prescribed groups of medications, especially in developing nations, owing to the vast number of infectious diseases prevalent in the community. Since the time of discovery of the phenomenal antimicrobial, penicillin, there has been a great rise in the number of antimicrobials in the market. Antibiotic resistance is increasing to dangerously high levels at national level as well at Global front. Novel resistance mechanisms are emerging and spreading globally, threatening our capability to treat common infectious diseases. Emergence and growth of superbugs is endangering our lives by making existing antibiotics worthless. Antimicrobial resistance is a prevalent danger. Immediate and coordinated measures must be taken worldwide to safeguard remaining antimicrobials and facilitate the development of novel antimicrobials. This review article brings to limelight, the recent drugs in the field of antimicrobial drug development, from the last 10 years till date.

KEY WORDS

Teixobactin, Tigecycline, Ceftaroline, Fidaxomicin.

Newer Antimicrobial Drugs

Teixobactin

Teixobactin is the first member of a novel class of peptidoglycan synthesis inhibitors¹. Teixobactin had excellent activity against Gram-positive pathogens, including drug-resistant strains. Potency against most species, including difficult-to-treat enterococci and M. tuberculosis was below 1nanogram ml. Teixobactin was exceptionally active against Clostridium difficile and Bacillus anthracis (minimal inhibitory concentration (MIC) of 5 and 20 ng ml, respectively^{2,3}.

Teixobactin is a promising therapeutic candidate; it is effective against drug-resistant pathogens in a number of animal models of infection. Binding of teixobactin to WTA precursor contributes to efficient lysis and killing, due to digestion of the cell wall by liberated autolysins. This is akin to the action of another natural product with excellent killing ability, acyldepsipeptide, which

converts the ClpP protease into a non-specific hydrolase that digests the cell⁴. These examples show that natural products evolved to exploit the inherent weaknesses of bacteria, and additional compounds that subvert important enzymes into killing devices are likely to be discovered. Teixobactin binds to multiple targets, none of which is a protein. Polyprenyl-coupled cell envelope precursors, such as lipid II, are readily accessible on the outside of Gram-positive bacteria and represent an 'Achilles heel' for antibiotic attack⁵. The target of teixobactin, the pyrophosphate-sugar moiety of these molecules, is highly conserved among eubacteria. The producer is a Gram-negative bacterium, and its outer membrane will protect it from re-entry of the compound. This suggests that the producer does not employ an alternative path-way for cell wall synthesis that would protect it from teixobactin, and which other bacteria could borrow. Resistance could eventually emerge from horizontal transmission of a resistance

mechanism from some soil bacterium, and given the highly conserved teixobactin binding motif, this would likely take the form of an antibiotic modifying enzyme. However, although determinants coding for enzymes attacking frequently found antibiotics such as β -lactams or aminoglycosides are common, they are unknown for the rare vancomycin. The recently discovered teixobactin is even less common than vancomycin. After its introduction into the clinic, it took 30 years for vancomycin resistance to appear. The lipid II modification pathway resulting in vancomycin resistance probably originated in the producer of vancomycin, *Amycolatopsis orientalis*⁶. It will probably take even longer for resistance to the better-protected teixobactin to emerge. Teixobactin is the first member of a new class of lipid II binding antibiotics, structurally distinct from glycopeptides, lantibiotics^{7,8}, and defensins⁹.

Tigecycline:

Tigecycline belongs to a class of drugs, closely related to tetracycline, called glycylcyclines. It inhibits protein synthesis by binding to the 30S ribosomal subunit and preventing the addition of transfer RNA molecules required for the elongation phase¹⁰. It is a bacteriostatic drug derived from minocycline and approved by the US Food and Drug Administration (FDA) for complicated intra-abdominal infections (cIAIs) and skin-soft tissue infections and community-acquired (CA) pneumonia¹¹⁻¹³. Tigecycline has a broader spectrum of activity against aerobic and anaerobic gram-negative and positive pathogens. *In vitro* data shows that tigecycline has very good antibacterial activity against ESBL as well. It is not active against *P. aeruginosa*, which is an important gap in its antimicrobial spectrum¹⁴. Tigecycline efficiently tackles ESBL-producing Enterobacteriaceae, CPKP, and *A. baumannii* (both MDR and XDR), while tribe Proteae and *Pseudomonas* are intrinsically resistant pathogens^{15, 16, 17}.

The clinical studies evaluating the efficacy of tigecycline usually depict the results of its combination with other drugs, thereby masking the real effect of the drug¹⁸⁻²¹. Combination with colistin, meropenem, or aminoglycoside has shown low failure rates in infections caused by XDR-CPKP. However, its excessive use has led to increasing resistance, especially in CPKP²². The common side effects include nausea, vomiting, and diarrhea. Its use has also showed controversy as the death rate is shown to be higher with this drug as

compared with other antibiotics, although the results were not statistically significant^{23, 24}.

Fidaxomicin:

Fidaxomicin is a narrow spectrum macrolide. It is mainly active against *Clostridium difficile*, and exerts limited activity against normal intestinal flora. It inhibits RNA polymerase sigma subunit that results in disruption of protein synthesis and cell death in susceptible organisms. It is purely bactericidal. It has minimal systemic absorption, has half-life of 9 hours and excreted mainly through faeces. It is given at a dose of 200 mg orally twice daily for 10 days. The most common adverse reactions reported in clinical trials are nausea, vomiting, gastrointestinal hemorrhage, abdominal pain, neutropenia and anaemia^{25, 26}. It is an alternative to the currently used treatment regimens of vancomycin and metronidazole against CDI. In a phase III trial ($n = 1000$), fidaxomicin 200 mg (twice a day) was found to be non-inferior to vancomycin 125 mg (four times a day) for the treatment of initial or first recurrences of CDI. Recurrence rates of CDI with fidaxomicin were significantly lower (13%) as compared to vancomycin (25%)²⁷.

Ceftaroline:

Ceftaroline is a novel fifth generation cephalosporin. It is available as Ceftaroline fosamil (a prodrug). It is converted to the bioactive form, ceftaroline in plasma by phosphatases. It is a broad-spectrum antibiotic that is highly effective against Methicillin Resistant *Staphylococcus aureus* (MRSA), penicillin and cephalosporin resistant *S. pneumoniae*, Vancomycin-intermediate *S. aureus* (VISA), and Vancomycin-resistant *S. aureus* (VRSA). Ceftaroline acts by binding to penicillin binding proteins. It shows high affinity for PBP2a present in *Staphylococcus aureus* that is responsible for methicillin resistance. In *S. pneumoniae*, ceftaroline binds to all 6 PBPs identified²⁸⁻³⁰. Inside the blood circulation, ceftaroline fosamil (prodrug) is rapidly converted to ceftaroline (active form) by phosphatase enzymes. It exhibits linear pharmacokinetics and has a serum half-life ($t_{1/2}$) of 1.6 hr (for a single dose) to 2.7 hr (following multiple doses). Volume of distribution (20 l) of ceftaroline is similar to that of other parenteral cephalosporins with plasma protein binding of 20%. Ceftaroline is metabolized by hydrolysis of its β -lactam ring which results into the formation of an inactive, open-ring metabolite called as ceftaroline M-1. It has a

low potential for drug interactions because of insignificant metabolism by CYP₄₅₀ enzymes³¹.

Ceftobiprole:

It is another newer cephalosporin which has completed its trial in 2007 and is awaiting FDA approval due to additional safety data being demanded by FDA. It is the broad-spectrum antibiotic which shows good spectrum of activity against MRSA, penicillin-resistant *S. pneumoniae*, *P. aeruginosa* and *Enterococci*. Ceftobiprole shows strong affinity for PBP2a of MRSA and PBP2x of *S. pneumoniae*. It is given as 1 hr IV infusion of 500 mg every 12 hrs for gram-positive infection and a 2 hr infusion of 500mg every 8 hrs for gram-negative. Dose adjustment is needed in patients with renal impairment^{32,33,34}

Dalbavancin:

It is a semisynthetic glycopeptide with a similar mode of action to vancomycin. It has potent activity against Gram-positive organisms including MRSA³⁵. Dalbavancin is highly potent against *S. pneumoniae*, *S. aureus*, coagulase-negative *Staphylococci* and vancomycin susceptible *Enterococci*. It is approved for the treatment of acute bacterial skin and skin structure infections caused mainly by Gram positive bacteria. The drug is to be infused IV over 30 minutes, only with 5% Dextrose as it gets precipitated with normal saline. Rapid infusion rates can lead to infusion reactions in form of upper body flushing, urticaria, pruritus, rash and ALT elevations > 3 times the Upper Normal Limit. Diarrhoea should be evaluated for *Clostridium difficile*-associated diarrhea (CDAD). Dalbavancin is 93% bound to albumin. It has an elimination half-life of around 346 hours. It is currently in trials for catheter related bloodstream infections^{36,37}.

Oritavancin:

Oritavancin is a phenyl glycopeptide derivative. It shares its structure with vancomycin, and inhibits peptidoglycan biosynthesis by inhibiting both transglycosylation and transpeptidation. It has a selective action due to its strong intramolecular interaction with D-amino acid-containing peptidoglycan residues, not found in mammalian cells. Its pharmacokinetic properties allow less frequent dosing and also improved distribution. The drug has good potency against *S. pneumoniae* and *Staphylococci*. It exerts concentration-dependent cell killing activity against vancomycin-intermediate isolates of *S. aureus* (VISA) including heterogeneous VISA (hVISA) and

against vancomycin resistant *Staphylococci* and *Enterococcus faecium* (VRE). It may also have additional activity against *B. anthracis*. It has a long elimination half-life of around 393 hours. A single 1200-mg dose administered IV over 3 hr is given for skin and skin structure infections³⁸⁻⁴⁰. Because of a long half-life, it is likely that it will be dosed on a daily or alternate day schedule³⁵

Telavancin:

Telavancin is highly potent against MRSA, *Streptococci* and Vancomycin resistant *Enterococcus* (VRE). The drug has been approved for complicated skin and skin structure infections, and for ventilator-associated bacterial pneumonia caused by *S. aureus*. It is 90% plasma protein bound and has an elimination half-life of around 8 hours. It is 76% excreted in urine. Hence, dosage adjustment is required in patients with severe renal impairment. For complicated skin and skin structure infections, an IV dose of 10 mg/kg is administered once a day for a period of 7 to 14 days. Adverse effects include taste disturbance, vomiting and foamy urine. Rapid IV infusion can cause "red man syndrome" like reactions. Diarrhea should be investigated for *Clostridium difficile*-associated diarrhea (CDAD). Possible additive effects with other drugs that prolong the QT interval have been seen⁴¹⁻⁴³.

Telavancin is rapidly bactericidal and exists as an intravenous preparation to be given once daily. Its current indication is in cSSTI⁴⁴.

Doripenem:

It is the newer parenteral carbapenem approved for the treatment of complicated urinary tract infections and intra-abdominal infections. The drug acts by binding to PBPs and thus inhibiting cross-linking of the peptidoglycan structure. The high binding affinity of doripenem to PBP-2 and -3 may enhance its activity against drug-resistant *P. aeruginosa*. Thus, it is a suitable alternative to currently available anti-pseudomonal carbapenems (i.e., imipenem, meropenem)⁴⁵. Doripenem has a unique spectrum of activity. It shows activity against gram-positive cocci like imipenem and activity against gram-negative bacilli like meropenem⁴⁶. Doripenem, like other carbapenems, is stable to ESBLs produced by *E. coli* and *Klebsiella* species and to AmpC β -lactamases enzymes; but it is vulnerable to certain acquired β -lactamases like class B metallo- β -lactamases produced by some *P. aeruginosa* isolates and carbapenemases produced by some Enterobacteriaceae

and *Acinetobacter* species⁴⁷. The elimination half-life is around 0.95 hr, and 75% of the drug is excreted unchanged in the urine, thus necessitating dosage adjustment in patients with renal impairment. It is administered as a 500 mg IV infusion, thrice daily for 5-14 days. Adverse events include anaemia, anaphylactic reactions, seizures, neutropenia, toxic epidermal necrolysis (TEN) and Stevens Johnson syndrome⁴⁸⁻⁵⁰.

Razupenem (PZ-601):

It is another novel carbapenem active against multi drug-resistant gram positive and gram-negative (ESBL producers) bacteria and is currently in trials for cSSSI⁵¹.

Retapamulin:

It is a novel topical antibiotic and the first approved member in this new class. It is approved for the treatment of skin and soft tissue infections caused by *S. pyogenes* and *S. aureus* which are resistant to the most commonly used topical antibiotics. It is ineffective against gram-negative organisms⁵². Retapamulin a pleuromutilin which is a protein synthesis inhibitor that acts by binding to 50-S subunit of bacterial ribosomes. It is bacteriostatic at MIC while it becomes bactericidal at 1000x MIC. It is 94% bound to plasma proteins and is metabolized mainly by CYP3A4. Pruritus at application site, bacterial or fungal superinfection on prolonged use including *Clostridium difficile* associated diarrhea (CDAD) and pseudomembranous colitis have been reported^{53,54}.

Telithromycin:

It is a protein synthesis inhibitor that blocks the progression of the growing polypeptide chain by binding to 50-S subunit of the bacterial ribosome. Telithromycin exhibits 10 times higher affinity to the subunit 50-S than erythromycin. Telithromycin is more active *in vitro* against *S. pneumoniae* compared with clarithromycin and azithromycin and maintains activity against macrolide resistant strains (*S. pneumoniae*, *S. pyogenes*)⁵⁵. Telithromycin is formulated as 400 mg tablet for oral administration. It is well absorbed orally with 60% bioavailability. Peak plasma concentration of 2.27 mg/l and a terminal half-life of 9.81 hr is achieved with a single 800 mg daily oral dose⁵⁶. Telithromycin is 66-89% bound to serum protein, principally albumin. Drug is cleared primarily by hepatic metabolism, 50% by CYP_{3A4} and 50% by CYP independent metabolism. No dose adjustment is required for patients of hepatic failure or mild to moderate renal disease⁵⁷.

Daptomycin:

It is a cyclic lipopeptide antibiotic derived from *Streptomyces roseosporus* and is the first member of this new class of antimicrobials. It was approved by FDA in 2003 for the treatment of SSTIs and approved in 2006 for the treatment of blood stream infections. It shows the unique mechanism of action by inserting its lipophilic tail into the cell membrane of gram-positive organisms without entering the bacterial cytoplasm. This calcium dependent process leads to the formation of channels from which intracellular potassium is lost disrupting the bacterial cell membrane potential and causing cell death⁵⁸. The dose giving maximum efficacy and safety is 4mg/kg daily as a once daily intravenous infusion, possibly due to the prolonged post-antibiotic effect of more than 6 hours. In healthy volunteers it has a half-life of 8 hours. It is excreted renally and consequently the dosage interval should be increased to every 48 hours in renal impairment where the creatinine clearance is <30ml/min or in patients on hemodialysis or continuous ambulatory peritoneal dialysis, where the half-life increases to 28 hours⁵⁹. Since it is not hepatically metabolized, it does not cause any interactions related to the cytochrome P-450 enzyme system^{60, 61}. It does not cross the blood brain barrier or enter the cerebrospinal fluid in normal individuals. Bone penetration is poor and daptomycin should therefore not be used in central nervous system or bone infections⁶². It has also not been effective in pneumonia, primarily due to daptomycin inactivation by lung surfactant⁶³.

Iclaprim:

It is a new dihydrofolate reductase inhibitor belonging to the same class of antibiotics as trimethoprim. Its Gram-positive cover is very promising with potent activity against MRSA, VISA and VRSA⁶⁴. It is a synthetic diaminopyrimidine, a selective inhibitor of the enzyme dihydrofolate reductase. Iclaprim is particularly potent against *S. pneumoniae* and *S. aureus*, including trimethoprim-resistant isolates. In contrast to trimethoprim which is most frequently used in combination with sulfamethoxazole, iclaprim is being developed for administration as a single agent, though highly synergistic activity was demonstrated with the sulfonamides like sulfamethoxazole, and sulfadiazine⁶⁵. Iclaprim displays linear pharmacokinetics. The protein binding of iclaprim is 92%-94% and half-life is 2-4 hr⁶⁶.

Torezolid:

It is the active moiety of the prodrug, torezolid phosphate, which has 4-16-fold greater potency than linezolid against gram-positive species including MRSA⁶⁷. It is an orally administered novel oxazolidinone. It is 4-8 times more active than linezolid in linezolid-susceptible and resistant strains of *Staphylococci* and *Enterococci* and up to 4 times higher activity against anaerobic bacteria. It has an oral bioavailability of 91% and hence no dosage adjustment is needed between IV and PO doses. It has an elimination half-life of around 12 hrs. It inhibits bacterial protein synthesis at the initiation/elongation step. It binds to the peptidyl transferase center (PTC) of 50S ribosome. It also binds to LepA, a universal bacterial elongation factor. Oxazolidinones bind only to the mitochondrial 70S ribosomes and not the cytoplasmic 80S ribosomes, explaining the myelosuppression and toxic optic neuropathy observed in linezolid-treated patients for as little as 14 days. Tedizolid is indicated in skin and skin structure infections. It is administered as 200 mg oral/IV for 6 days. Adverse events associated may include nausea, headache, anaemia, flushing, hypertension and *C.difficile* colitis⁶⁸⁻⁷⁰.

Raxibacumab:

It is a recombinant human monoclonal antibody that has been recently developed against Anthrax infections. It can be used both as a prophylactic agent as well as a therapeutic agent. It is highly effective when given in combination with drugs used against *B.anthraxis*. The drug targets the protective antigen component of the lethal toxin of the Anthrax bacillus. Common adverse events reported are headache, nausea, respiratory infections, pruritis and pain in the extremities⁷¹⁻⁷³.

Bedaquiline:

The U.S. Food and Drug Administration (FDA) has approved Bedaquiline for use as part of a combination therapy in adults with pulmonary multidrug-resistant tuberculosis (MDR TB). It inhibits proton pump of mycobacterial ATP synthase by binding to the oligomeric and proteolipic subunit-C of mycobacterial ATP synthase. This leads to inhibition in ATP synthesis and hence bacterial death. Bedaquiline has a half-life of 4-5 months. Increased mortality, QT prolongation, raised liver enzymes, hemoptysis and chest pain are reported adverse events with bedaquiline. It is dosed as follows: Weeks 1 - 2: 400 mg (oral) once daily; Weeks 3 - 24: 200 mg (oral) three times in a week^{74,75}.

Finafloxacin:

It is a fluoroquinolone antibiotic that has been approved recently by the US FDA for swimmer's ear, scientifically termed as acute otitis externa. It is highly active against *Pseudomonas aeruginosa* and *Staphylococcus aureus*. It is available as a topical formulation in the form of eardrops / otic suspension. Commonly reported adverse events include local pruritis and nausea. Also, hypersensitivity reactions may be seen with the drug. It is also being used for the treatment of urinary tract infections^{76, 77}.

CONCLUSION:

As more resistant organisms are being seen in clinical practice, there is an urgent need for more potent antibiotics. There are only a few drugs which belong to a completely novel class; the rest are only a development of old and existing classes. If we do not take good care of the existent antibiotics by responsible prescribing, we will be at risk of losing even these more efficacious antibiotics. Antibiotics tend to lose their efficacy over time due to the emergence and dissemination of resistance among bacterial pathogens. Strains with resistance to multiple antibiotic classes have emerged among major Gram-positive and Gram-negative species including *Staphylococcus aureus*, *Enterococcus* spp., *Pseudomonas aeruginosa*, *Acinetobacter* spp. Enterobacteriaceae, and *Neisseria gonorrhoeae*. With some Gram-negatives, resistance may involve most or even all the available antimicrobial options, resulting in extremely drug-resistant or totally drug-resistant phenotypes. This so-called 'antibiotic resistance crisis' has been compounded by the lagging in antibiotic discovery and development programs occurred in recent years, and is jeopardizing the essential role played by antibiotics in current medical practices.

The emergence of pathogens with a variety of resistance mechanisms has intensified the challenges associated with infection control and treatment strategies. Therefore, prudent use of currently available antimicrobial agents, as well as implementing measures to limit spread of resistance is paramount. Although several new antimicrobials have been recently approved or are in the pipeline showing promise in the battle against resistance, the appropriate use of these agents is required as the true benefits of these

treatments are to be recognized in the clinical care setting.

ACKNOWLEDGEMENT

We would like to thank Department of Pharmaceutical Sciences, University of Kashmir, Hazratbal Srinagar-190006 for their support and valuable suggestions.

REFERENCES:

- Laura J. V. Piddock, Teixobactin, the first of a new class of antibiotics discovered by iChip technology? *J Antimicrob Chemother.* 2015 Oct;70(10):2679-80.
- Sakoulas, G. et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant *Staphylococcus aureus* bacteremia. *J. Clin. Microbiol.* 42, 2398-2402 (2004).
- Kollef, M. H. Limitations of vancomycin in the management of resistant staphylococcal infections. *Clin. Infect. Dis.* 45 (Suppl 3). S191-S195 (2007).
- Conlon, B. P. et al. Activated ClpP kills persisters and eradicates a chronic biofilm infection. *Nature* 503, 365–370 (2013).
- Schneider, T. & Sahl, H. G. An oldie but a goodie—cell wall biosynthesis as antibiotic target pathway. *Int. J. Med. Microbiol.* 300, 161–169 (2010).
- Leclercq, R., Derlot, E., Duval, J. & Courvalin, P. Plasmid-mediated resistance to vancomycin and teicoplanin in *Enterococcus faecium*. *N. Engl. J. Med.* 319, 157–161 (1988).
- Wiedemann, I. et al. Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. *J. Biol. Chem.* 276, 1772–1779 (2001).
- Hasper, H. E. et al. An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II. *Science* 313, 1636–1637 (2006).
- Schneider, T. et al. Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II. *Science* 328, 1168–1172 (2010).
- Zhanell GG, Karlowsky JA, Rubinstein E, Hoban DJ. Tigecycline: a novel glycylcycline antibiotic. *Expert Rev Anti-Infect Ther* 2006; 4(1):9-2565. Giamarellou H, Poulakou G. Multidrug-resistant Gram-negative infections: what are the treatment options? *Drugs.* 2009;69(14):1879–1901.
- Hanberger H, Giske CG, Giamarellou H. When and how to cover for resistant Gram-negative bacilli in severe sepsis and septic shock. *Curr Infect Dis Rep.* 2011;13(5):416–425.
- Stein GE, Babinchak T. Tigecycline: an update. *Diagn Microbiol Infect Dis.* 2013;75(4):331–336.
- Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. *Diagn Microbiol Infect Dis.* 2000; 36:19–36.
- Stein GE, Babinchak T. Tigecycline: an update. *Diagn Microbiol Infect Dis.* 2013;75(4):331–336.
- Castanheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo- beta-lactamase-producing *Enterobacteriaceae*: report from the SENTRY Antimicrobial Surveillance Program. *Antimicrob Agents Chemother.* 2008;52(2):570–573.
- Zarkotou O, Pournaras S, Altouvas G, et al. Comparative evaluation of tigecycline susceptibility testing methods for expanded-spectrum cephalosporin- and carbapenem-resistant Gram-negative pathogens. *J Clin Microbiol.* 2012; 50:3747–3750.
- Tzouveleakis LS, Markogiannakis A, Psychogiou M, Tassios PT, Daikos GL. Carbapenemases in *Klebsiella pneumoniae* and other *Enterobacteriaceae*: an evolving crisis of global dimensions. *Clin Microbiol Rev.* 2012;25(4):682–707.
- Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline. *Clin Infect Dis.* 2008;46(4):567–570.
- Curcio D, Fernandez F, Vergara J, Vazquez W, Luna CM. Late onset ventilator-associated pneumonia due to multidrug-resistant *Acinetobacter* spp.: experience with tigecycline. *J Chemother.* 2009;21(1):58–62.
- Kontopidou F, Giamarellou H, Katerelos P, et al. Infections caused by carbapenem-resistant *Klebsiella pneumoniae* among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. *Clin Microbiol Infect.* 2014;20(2):O117–O123.
- Nigo M, Cevallos CS, Woods K, et al. Nested case-control study of the emergence of tigecycline resistance in multidrug-resistant *Klebsiella pneumoniae*. *Antimicrob Agents Chemother.* 2013;57(11):5743–5746.
- FDA A Drug Safety Communication: Increased Risk of Death with Tygacil (tigecycline) Compared to Other Antibiotics Used to Treat Similar Infections. 2010. Available at: <http://www.fda.gov/Drugs/DrugSafety/>.
- FDA A Drug Safety Communication: FDA Warns of Increased Risk of Death with IV Antibacterial Tygacil (tigecycline) and Approves New Boxed Warning. 2013. Available at: <http://www.fda.gov/>.
- Goldstein EJC, Babakhani F, Citron DM. Antimicrobial activities of fidaxomicin *Clin Infect Dis* 2012; 55(Suppl 2): S143–S148.
- Artisimovitch I, Seddon J, Sears P. Fidaxomicin Is an Inhibitor of the Initiation of Bacterial RNA Synthesis. *Clin Infect Dis.* 2012; 55(Suppl 2): S127–S131.
- Poxton IR. Fidaxomicin: A new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of

- Clostridium difficile infection. *Future Microbiol.* 2010; 5:539–48.
27. Ghamrawi RJ, Neuner E, Rehm SJ. Ceftaroline fosamil: A super-cephalosporin? *Cleve Clin J Med* 2015;82(7):437-44.
28. Candel FJ, Baos E, Nieto M, Picazo JJ. Could ceftaroline be an alternative therapy for linezolid resistant Staphylococcus epidermidis infections in Intensive Care Medicine? *Rev Esp Quimioter* 2015;28(4):214-6.
29. Kaye KS, Udeani G, Cole P, Friedland HD. Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia. *Hosp Pract* 2015;43(3):144-9.
30. Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. *Antimicrob Agents Chemother.* 2007; 51:3612–6.
31. Widmer AF. Ceftobiprole: A new option for treatment of skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus. *Clin Infect Dis.* 2008; 46:656–8.
32. Kosowska K, Hoellman DB, Lin G, Clark C, Credito K, McGhee P, et al. Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. *Antimicrob Agents Chemother.* 2005; 49:1932–42.
33. Chahine EB, Nornoo AO. Ceftobiprole: The first broad spectrum anti-methicillin-resistant Staphylococcus aureus beta-lactam. *J Exp Clin Med.* 2011; 3:9–16.
34. Drew RH. Emerging options for treatment of invasive multidrug-resistant Staphylococcus aureus infections. *Pharmacotherapy.* 2007; 27(2):227-49.
35. Scott LJ. Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections. *Drugs* 2015;75(11):1281-91.
36. Gupta AK, Foley KA, Abramovits W, Rosen T. Dalbavancin (Dalvance) for the treatment of acute bacterial skin infection. *Skinmed* 2014;12(6):366-9.
37. Henson KE, Levine MT, Wong EA, Levine DP. Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile. *Expert Rev Anti Infect Ther* 2015;1-14.
38. Saravolatz LD, Stein GE. Oritavancin: A Long-Half-Life Lipoglycopeptide *Clin Infect Dis* 2015;61(4):627-32.
39. Messina JA, Fowler VG Jr, Corey GR. Oritavancin for acute bacterial skin and skin structure infections *Expert Opin Pharmacother* 2015;16(7):1091-8.
40. Chan C, Hardin TC, Smart JI. A review of telavancin activity in in vitro biofilms and animal models of biofilm-associated infections. *Future Microbiol* 2015;10(8):1325-38.
41. Nawar T, Kanafani ZA. Telavancin (VIBATIV) for the treatment of complicated skin and skin structure infections. *Expert Rev Anti Infect Ther.* 2015;13(7):825-33.
42. Nnedu ON, Pankey GA. Update on the emerging role of telavancin in hospital-acquired infections. *Ther Clin Risk Manag.* 2015; 11:605-10.
43. Stryjewski ME, O’Riordan WD, Lau WK, Pien FD, Dunbar LM, Vallee, M. et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria. *Clin Infect Dis* 2005; 20:1601-7.
44. Jones RN, Huynh HK, Biedenbach DJ. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. *Antimicrob Agents Chemother.* 2004; 48:3136–40.
45. Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): A global surveillance report (2003) *Clin Microbiol Infect.* 2005; 11:974–84.
46. Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: Activity against characterized isolates, mutants, and transconjugants and resistance selection potential. *Antimicrob Agents Chemother.* 2004; 48:3086–92.
47. Qu XY, Hu TT, Zhou W. A meta-analysis of efficacy and safety of doripenem for treating bacterial infections. *Braz J Infect Dis* 2015;19(2):156-62.
48. Cannon JP, Lee TA, Clark NM, Setlak P, Grim SA. The risk of seizures among the carbapenems: a meta-analysis *J Antimicrob Chemother* 2014;69(8):2043-55.
49. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. *Antimicrob Agents Chemother.* 2011;55(11):4943-60.
50. Livermore DM, Mushtaq S, Warner M. Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms. *J Antimicrob Chemother.* 2009; 64:330–5.
51. Yang LP, Keam SJ. Spotlight on retapamulin in impetigo and other uncomplicated superficial skin infections. *Am J Clin Dermatol.* 2008; 9:411–3.
52. Mundy LM, Sampson T, Logie JW. Retapamulin prescriptions and monitored off-label use. *Paediatr Drugs* 2014;16(4):331-6.
53. Dhingra D, Parakh A, Ramachandran S. Retapamulin: a newer topical antibiotic *J Postgrad Med* 2013;59(2):127-30.
54. Zuckerman JM. Macrolides and ketolides: Azithromycin, clarithromycin, telithromycin. *Infect Dis Clin North Am.* 2004; 18:621–49.
55. Namour F, Wessels DH, Pascual MH, Reynolds D, Sultan E, Lenfant B. Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. *Antimicrob Agents Chemother.* 2001; 45:170–5.
56. US Food and Drug Administration: Department of Health and Human Services. Telithromycin (marketed as Ketek) information. [Last accessed on 2012 Jan 13]. Available from: <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107824.htm>.

57. Hobbs JK, Miller K, O' Neill AJ, Chopra L. Consequences of daptomycin-mediated membrane damage in *Staphylococcus aureus*. *Antimicrob Chemother*. 2008; 62:1003–8.
58. Novartis Pharmaceuticals UK Ltd. Cubicin powder for concentrate for solution for infusion. [homepage on the Internet]. 2006 November 20 [cited 2007 March 21]; Available from: URL: <http://emc.medicines.org.uk/>
59. Tedesco KL, Rybak MJ. Daptomycin Pharmacotherapy. 2004; 24(1):41-57.
60. Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. *J Antimicrob Chemother* 2005; 55:283-8.
61. Pham PA. FDA approves daptomycin, a new cyclic lipopeptide antibiotic, for the treatment of resistant gram-positive organisms. [homepage on the Internet]. John Hopkins Division of Infectious Diseases Antibiotic Guide 2001-2004 [cited 2007 March 21]; Available from:URL: http://hopkins-abxguide.org/show_pages.cfm?content=F40_100803_content.html
62. Paterson DL. Clinical experience with recently approved antibiotics. *Curr Opin Pharmacol* 2006; 6:486-90.
63. Hawser S, Lociuro S, Islam K. Dihydrofolate reductase inhibitors as antibacterial agents. *Biochem pharmacol* 2006; 71:941-8.
64. Laue H, Weiss L, Bernardi A, Hawser S, Lociuro S, Islam K. In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action. *J Antimicrob Chemother*. 2007; 60:1391–4.
65. Andrews J, Honeybourne D, Ashby J, Jevons G, Fraise A, Fry P, et al. Concentrations in plasma, epithelial lining fluid, alveolar macrophages and bronchial mucosa after a single intravenous dose of 1.6 mg/kg of iclaprim (AR-100) in healthy men. *J Antimicrob Chemother*. 2007; 60:677–80.
66. Prokocimer P, Bien P, Surber J, Mehra P, DeAnda C, Bulitta JB, et al. A phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. *Antimicrob Agents Chemother*. 2011; 55:583–92.
67. Hui Y, Xiaoju L. Tedizolid for treatment of acute bacterial skin and skin structure infections. *Expert Rev Anti Infect Ther* 2015;1-10.
68. Chahine EB, Sucher AJ, Knutsen SD. Tedizolid: A New Oxazolidinone Antibiotic for Skin and Soft Tissue Infections. *Consult Pharm* 2015;30(7):386-94.
69. Burdette SD, Trotman R. Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic. *Clin Infect Dis* 2015 Oct 15;61(8):1315-21.
70. Nestorovich EM, Bezrukov SM. Designing inhibitors of anthrax toxin. *Expert Opin Drug Discov* 2014;9(3):299-318.
71. Migone TS, Bolmer S, Zhong J, Corey A, Vasconcelos D, Buccellato M et al. Added benefit of raxibacumab to antibiotic treatment of inhalational anthrax. *Antimicrob Agents Chemother* 2015;59(2):1145-51.
72. Kummerfeldt CE. Raxibacumab: potential role in the treatment of inhalational anthrax. *Infect Drug Resist* 2014; 7:101-9.
73. Salfinger M, Migliori GB. Bedaquiline: finding the pores on the pot. *Eur Respir J* 2015;46(1):289-91.
74. Field SK. Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment? *Ther Adv Chronic Dis* 2015;6(4):170-84.
75. Bartoletti R, Cai T, Perletti G, Me Wagenlehner F, Bjerklund Johansen TE. Finafloxacin for the treatment of urinary tract infections. *Expert Opin Investig Drugs* 2015;24(7):957-63.
76. McKeage K. Finafloxacin: first global approval. *Drugs* 2015;75(6):687-93.

Received:02.05.18, Accepted: 05.06.18, Published:01.07.2018

***Corresponding Author:**

Geer Mohamed Ishaq*

Email: ishaggeer@gmail.com